| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Internal Medicine (W.d.R., H.A.P.P., F.H.d.J.), Erasmus Medical Center, 3000 DR Rotterdam, The Netherlands; Julius Center for Health Sciences and Primary Care (Y.T.v.d.S., M.M., D.E.G.), University Medical Center 3508 GA Utrecht, The Netherlands; Department of Endocrinology (W.d.R., L.J.G.G.), Vrije Universiteit Medical Center, 1007 MB Amsterdam, The Netherlands; and Department of Epidemiology and Biostatistics (H.A.P.P.), Erasmus Medical Center, 3000 DR Rotterdam, Netherlands
Address all correspondence and requests for reprints to: Frank H. de Jong, Ph.D., Endocrine Laboratory, Room Ee 516, Department of Internal Medicine, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands. E-mail: f.h.dejong{at}erasmusmc.nl.
Results of in vitro experiments indicate that with increasing concentrations of SHBG, testosterone (T) is preferentially bound to SHBG in comparison with estradiol (E2). In these studies, the ratio of non-SHBG-bound E2 (non-SHBG-E2) to non-SHBG-T increased with increasing levels of SHBG. SHBG has consequently been regarded as an estrogen amplifier. In this cross-sectional study in 399 men aged between 40 and 80 yr we tested whether higher levels of SHBG are associated with a higher estrogen/androgen ratio in vivo. The mean T level of these men was in the eugonadal range [536 ± 152 ng/dl (18.6 ± 5.26 nmol/liter), mean ± SD]. With increasing SHBG levels the non-SHBG-bound fraction of T decreased from 80 to 36% and that of E2 from 89 to 53%. Higher levels of SHBG were associated with higher levels of both total T [regression coefficient (ß) after adjustment for age and body mass index, 286 ± 15.8; P < 0.001] and total E2 (ß = 4.47 ± 0.90; P < 0.001). However, SHBG levels were negatively related with levels of non-SHBG-E2 (ß = 1.78 ± 0.69; P < 0.001), whereas there was a positive association between levels of SHBG and non-SHBG-T (ß = 32.0 ± 9.78; P = 0.001). Furthermore, we observed a negative relationship between SHBG levels and the E2/T ratio of either total (ß = 0.016 ± 0.002; P < 0.001) or non-SHBG-bound (ß = 0.011 ± 0.002; P < 0.001) hormone. Therefore, we conclude that in eugonadal men, higher SHBG levels are associated with lower levels of non-SHBG-E2 but slightly higher levels of non-SHBG-T. This means that SHBG cannot be regarded as an estrogen amplifier in eugonadal men.
This article has been cited by other articles:
![]() |
G. F. Kerkhof, R. W. J. Leunissen, R. H. Willemsen, F. H. de Jong, T. Stijnen, and A. C. S. Hokken-Koelega Influence of Preterm Birth and Birth Size on Gonadal Function in Young Men J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4243 - 4250. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Parent, C. S. Dence, T. L. Sharp, M. J. Welch, and J. A. Katzenellenbogen 7{alpha}-18F-Fluoromethyl-Dihydrotestosterone and 7{alpha}-18F-Fluoromethyl-Nortestosterone: Ligands to Determine the Role of Sex Hormone-Binding Globulin for Steroidal Radiopharmaceuticals J. Nucl. Med., June 1, 2008; 49(6): 987 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. Virtanen, A. E. Tapanainen, M. M. Kaleva, A.-M. Suomi, K. M. Main, N. E. Skakkebaek, and J. Toppari Mild Gestational Diabetes as a Risk Factor for Congenital Cryptorchidism J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4862 - 4865. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Raven, F. H. de Jong, J.-M. Kaufman, and W. de Ronde In Men, Peripheral Estradiol Levels Directly Reflect the Action of Estrogens at the Hypothalamo-Pituitary Level to Inhibit Gonadotropin Secretion J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3324 - 3328. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. de Ronde, Y. T. van der Schouw, H. A.P. Pols, L. J.G. Gooren, M. Muller, D. E. Grobbee, and F. H. de Jong Calculation of Bioavailable and Free Testosterone in Men: A Comparison of 5 Published Algorithms Clin. Chem., September 1, 2006; 52(9): 1777 - 1784. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Bilezikian What's Good for the Goose's Skeleton is Good for the Gander's Skeleton. J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1223 - 1225. [Full Text] [PDF] |
||||
![]() |
E. Orwoll, L. C. Lambert, L. M. Marshall, K. Phipps, J. Blank, E. Barrett-Connor, J. Cauley, K. Ensrud, S. Cummings, and for the Osteoporotic Fractures in Men Study Group Testosterone and Estradiol among Older Men J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1336 - 1344. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Severi, H. A. Morris, R. J. MacInnis, D. R. English, W. Tilley, J. L. Hopper, P. Boyle, and G. G. Giles Circulating Steroid Hormones and the Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 86 - 91. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. den Brinker, K. F. M. Joosten, O. Liem, F. H. de Jong, W. C. J. Hop, J. A. Hazelzet, M. van Dijk, and A. C. S. Hokken-Koelega Adrenal Insufficiency in Meningococcal Sepsis: Bioavailable Cortisol Levels and Impact of Interleukin-6 Levels and Intubation with Etomidate on Adrenal Function and Mortality J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5110 - 5117. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |